- MediciNova ( NASDAQ: MNOV ) said it received a notice of allowance from the Canadian Intellectual Property Office for a patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) to treat scleroderma and/or systemic sclerosis.
- Scleroderma, also known as systemic sclerosis, is a group of rare diseases which involve the hardening of the skin and may also cause issues in the blood vessels and internal organs.
- The patent is expected to expire not before June 2035.
- The allowed claims cover the use of MN-001 (tipelukast) or MN-002 for treating scleroderma and for reducing and/or inhibiting elevated hydroxyproline levels in scleroderma/systemic sclerosis.
- The claims also cover oral administration including liquid and solid dosage forms, and range of doses and dosing frequencies.
- "This new patent approval is based on positive results in a systemic sclerosis animal model study conducted previously," said MediciNova Chief Medical Officer Kazuko Matsuda.
For further details see:
MediciNova to get Canadian patent linked to potential skin disorder therapy